News and Events
SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs) Authors: Philip M. Arlen, MD; Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata,...
Immuno-Oncology Europe 2019
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO, Precision Biologics, Inc, United States of America An allogeneic cancer vaccine developed from human tumors surgically resected had...
Novel Targets Of Neoantigens In Monoclonal Antibodies
Philip M. Arlen, M.D.Summary: Target is broadly expressed in multiple solid tumors.Exhibits both ADCC and CDC killing.Promising pre-clinical results with complete regression of tumor in animal models.GMP manufacturing completed.Pre-clinical testing showed...
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION – Cambridge Healthtech Institute August 8-9, 2019
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology at the Cambridge Healthtech Institute’s 4th Annual Neoantigen Targeted Therapies Personalized Cancer...
2019 ASCO Annual Meeting
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Session Title/Date/Time: Poster Session: Developmental Immunotherapy and Tumor Immunobiology, 6/1/2019, 8:00 AM-11:00 AM May 31 – June 4, 2019...
Precision Biologics and NCI investigators to discuss NEO-201 development program at First Internation Congress of Bioimmunotherapy of Cancer
First international congress of BIOIMMUNOTHERAPY OF CANCER An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala Perri, Piazza Italia, 89125 Reggio Calabria
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. Cancer Biother Radiopharm. 2019 Apr;34(3):147-159.
AACR Annual Meeting
Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019 - Atlanta, Georgia Session Category: Clinical Research Session Title: Immunomodulation by Chemotherapy and Targeted Agents Session Date and...
Dr. Philip M Arlen to deliver to presentations on the NEO-201 program at the Molecular Med Tri-Con Meetings, March 10-15th, SF, CA
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen Philip M. Arlen, M.D.March, 2019
The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients with advanced solid tumors may be eligible to participate in a new clinical trial at the NIH Clinical Center.